Table 2.

Baseline characteristics by albuminuria and SBP reduction at month 6a

CharacteristicrALB ≤0%/rSBP ≤0 mmHg(n = 322)rALB ≤0%/rSBP >0 mmHg(n = 297)rALB >0%/rSBP ≤0 mmHg(n= 309)rALB >0%/rSBP >0 mmHg(n = 500)
Male gender (%)207 (64.3)195 (65.7)183 (59.2)319 (63.8)
Race (%)
    Asian51 (15.8)42 (14.1)61 (19.7)87 (17.4)
    black54 (16.8)41 (13.8)53 (17.2)67 (13.4)
    Hispanic70 (21.7)56 (18.9)54 (17.5)85 (17.0)
    white141 (43.8)157 (52.9)135 (43.7)257 (51.4)
Smoking (yes; %)b64 (19.9)48 (16.2)47 (15.3)99 (19.8)
Duration of hypertension (≥10 yr)b99 (36.9)84 (33.9)105 (39.0)175 (40.0)
α blockerc76 (23.6)66 (22.2)74 (23.9)128 (25.6)
β blockerc64 (19.9)49 (16.5)55 (17.8)94 (18.8)
CCB dihydropyridinec56 (17.4)71 (23.9)65 (21.0)108 (21.6)
CCB nondihydropyridinec178 (55.3)160 (53.9)162 (52.4)278 (55.6)
ACEi or ARBc166 (51.6)158 (53.2)144 (46.6)270 (54.0)
Heart failure (yes; %)13 (4.0)14 (4.7)16 (5.2)32 (6.4)
PVD (yes; %)26 (8.1)36 (12.1)41 (13.3)68 (13.6)
Angina (yes; %)30 (9.3)35 (11.8)21 (6.8)54 (10.8)
Myocardial infarction (yes; %)33 (10.2)38 (12.8)30 (9.7)51 (10.2)
IHD (yes; %)93 (28.9)102 (34.3)84 (27.2)177 (35.4)
Age (yr)59.7 ± 7.360.3 ± 7.860.8 ± 7.360.0 ± 7.2
BMI (kg/m2)29.6 ± 6.129.5 ± 6.029.6 ± 6.529.9 ± 6.4
SiSBP (mmHg)143.3 ± 18.0160.5 ± 18.8144.7 ± 17.0160.1 ± 19.3
SiDBP (mmHg)80.2 ± 10.684.9 ± 10.780.4 ± 11.184.4 ± 10.8
Pulse rate (beats/min)75.5 ± 9.974.9 ± 9.474.5 ± 10.375.4 ± 10.3
Urine alb/creat ratio (mg/g)1573.3 ± 1417.21477.4 ± 1360.21895.8 ± 1803.22114.2 ± 1934.3
    geometric mean971.3982.71180.11363.2
Serum creatinine (mg/dl)1.8 ± 0.51.9 ± 0.51.9 ± 0.51.9 ± 0.5
Serum albumin (mg/dl)3.8 ± 0.43.8 ± 0.43.8 ± 0.53.8 ± 0.4
Hemoglobin (mg/dl)12.5 ± 1.812.5 ± 1.912.4 ± 1.812.6 ± 1.8
Total cholesterol (mg/dl)232.6 ± 60.8224.1 ± 53.0226.7 ± 51.4227.1 ± 56.2
LDL (mg/dl)143.9 ± 49.9139.9 ± 43.0142.7 ± 45.5141.3 ± 45.4
HDL (mg/dl)44.6 ± 14.244.4 ± 14.446.2 ± 15.445.1 ± 15.5
Serum triglycerides (mg/dl)231.8 ± 202.0222.8 ± 228.9206.1 ± 148.2215.8 ± 184.4
    geometric mean190.0177.9173.3177.3
  • a Data are n (%) or means ± SD. ACEi, angiotensin-converting enzyme inhibitor; alb/creat, albumin/creatinine; ARB, angiotensin II receptor blocker; BMI, body mass index; CCB, calcium channel blocker; IHD, ischemic heart disease; PVD, peripheral vascular disease; rALB, reduction in albuminuria; rSBP, reduction in SBP; SiDBP, sitting diastolic BP; SiSBP, sitting SBP.

  • b Percentage was calculated on the basis of number of patients without missing values.

  • c Antihypertensive therapies before study initiation.